



## **HRA Pharma completes acquisition of Lysodren®**

**Paris, France, March 15, 2018** – HRA Pharma, a fast-growing, innovative healthcare company, today announced that it has completed the acquisition of Lysodren® (mitotane tablets) from Bristol-Myers Squibb Company (NYSE:BMJ). As part of the transaction, the transfer of ownership from Bristol-Myers Squibb to HRA Pharma occurred on March 14, 2018.

Lysodren is a chemotherapy drug used for symptomatic treatment of advanced adrenal cortical carcinoma, a rare cancer of the adrenal glands. It is taken in tablet form and requires active medical monitoring.

In Europe, Lysodren has been distributed by HRA Pharma under a licensing agreement with Bristol-Myers Squibb since 2002. The current transaction gives HRA Pharma the development, manufacture and commercialization rights to the medicine in all markets, including Europe, the United States, Canada, Brazil and South Korea, as well as a named patient basis distribution in a number of additional geographies.

“With this product acquisition, we expand the international reach of our Endocrinology and Rare Disease Division and strengthen our position as a key player in Cushing’s syndrome and Adrenal Cortical Carcinoma,” said David Wright, CEO of HRA Pharma.

HRA Pharma has a fully-dedicated Endocrinology & Rare Diseases division that operates separately from the main Consumer Healthcare Business. The mission of this Endocrinology & Rare Diseases division is to make meaningful health solutions broadly accessible to rare disease patients. With a portfolio of medicines that address Cushing’s syndrome and Adrenal Cortical Carcinoma, the company’s goal is to support rare disease patients and healthcare providers with appropriate products and services from diagnosis to treatment follow-up.

## **About HRA Pharma**

HRA Pharma is a fast growing, innovative healthcare company empowering people throughout the world to improve their lives by developing accessible, value added, healthcare solutions. With ambitious projects in the pipeline, HRA Pharma is committed to bringing a range of innovative products and services to market, particularly in areas of unmet customer needs. Headquartered in Paris, France with subsidiaries across Western Europe and a global network of local partners covering over 90 countries, the company has a proven structure, the skills and experience to capture new healthcare businesses and deliver high quality brands on a global scale. Visit [www.hra-pharma.com](http://www.hra-pharma.com) for more information.

###

## **Media contact**

Karina Bugnon

Tel - +33 (0) 1 40 33 11 30

Email – [k.bugnon@hra-pharma.com](mailto:k.bugnon@hra-pharma.com)